Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07614776 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
A Phase 3 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
NCT07614776 is a Phase 3 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 304 participants.
The verdict
NCT07614776, a Phase 3 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
Study Summary
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)
Interventions
- DRUG ABP 938 8 mg
- DRUG Aflibercept (US) 8 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2026-05-27 |
| Est. Completion | 2028-01-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07614776
The ClinicalTrials.gov registry entry for NCT07614776 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABP 938 8 mg is the first listed.
NCT07614776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07614776 about?
NCT07614776 is a clinical study titled "A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration". The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)
What is the current status of trial NCT07614776?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2026-05-27. Estimated completion is 2028-01-12.
What interventions are being tested in trial NCT07614776?
The interventions under investigation include: ABP 938 8 mg (DRUG), Aflibercept (US) 8 mg (DRUG).
Who is sponsoring clinical trial NCT07614776?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.